Stock NVAX NOVAVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
15.04 USD -1.38% Intraday chart for Novavax, Inc. -2.97% +213.33%
May. 24 Novavax awaits FDA decision on whether its next COVID shot can be offered in US RE
May. 23 Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024 CI

Business Summary

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Number of employees: 1,543

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Vaccines
100.0 %
1,982 100.0 % 984 100.0 % -50.36%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1,982 100.0 % 984 100.0 % -50.36%

Managers

Managers TitleAgeSince
John Jacobs CEO
 Chief Executive Officer 57 23-01-22
John Trizzino PSD
 President 64 14-03-09
James Kelly DFI
 Director of Finance/CFO 58 21-08-15
Troy Morgan CMP
 Compliance Officer - 21-04-18
Raburn Mallory CTO
 Chief Tech/Sci/R&D Officer - 19-12-31
Seth Toback CTO
 Chief Tech/Sci/R&D Officer - 20-06-30
Gale Smith CTO
 Chief Tech/Sci/R&D Officer - 03-12-31
Filip Dubovsky CTO
 Chief Tech/Sci/R&D Officer 59 20-06-16
Biegie Lee CTO
 Chief Tech/Sci/R&D Officer - 16-12-31
Silvia Taylor IRO
 Public Communications Contact - 20-06-16

Members of the board

Members of the board TitleAgeSince
Richard Rodgers BRD
 Director/Board Member 57 22-10-28
Gregg Alton BRD
 Director/Board Member 58 20-10-31
David Mott BRD
 Director/Board Member 58 20-06-15
James Young CHM
 Chairman 71 10-04-06
Margaret McGlynn BRD
 Director/Board Member 64 20-12-06
Rachel King BRD
 Director/Board Member 64 18-10-31
Richard Douglas BRD
 Director/Board Member 71 10-08-05
John Jacobs CEO
 Chief Executive Officer 57 23-01-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 141,745,693 133,438,476 ( 94.14 %) 1,327,717 ( 0.9367 %) 94.14 %

Shareholders

NameEquities%Valuation
STATE STREET CORPORATION
12.08 %
16,906,570 12.08 % 67 M $
Vanguard Fiduciary Trust Co.
9.641 %
13,493,274 9.641 % 53 M $
Shah Capital Management, Inc.
7.835 %
10,965,794 7.835 % 43 M $
BlackRock Advisors LLC
6.297 %
8,813,440 6.297 % 35 M $
Shah Capital Management, Inc.
5.800 %
8,117,827 5.800 % 32 M $
SK BIOSCIENCE CO.,LTD.
4.644 %
6,500,000 4.644 % 26 M $
Geode Capital Management LLC
1.849 %
2,587,734 1.849 % 10 M $
Morgan Stanley Investment Management, Inc.
1.336 %
1,870,330 1.336 % 7 M $
Citigroup Global Markets, Inc. (Broker)
1.255 %
1,755,810 1.255 % 7 M $
Rafferty Asset Management LLC
1.202 %
1,682,659 1.202 % 7 M $

Company contact information

Novavax, Inc.

700 Quince Orchard Road

20878, Gaithersburg

+240 268 2000

http://www.novavax.com
address Novavax, Inc.(NVAX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Novavax, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.03 USD
Average target price
21.6 USD
Spread / Average Target
+43.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NOVAVAX, INC. Stock Novavax, Inc.
+213.33% 2.11B
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. Company Novavax, Inc.